Nuclear factor-κ13 in development, prevention, and therapy of cancer

被引:254
作者
Van Waes, Carter
机构
[1] Natl Inst Deafness & Other Commun Disorders, Head & Neck Surg Branch, Bethesda, MD 20892 USA
[2] NCI, Ctr Canc Res, Bethesda, MD 20892 USA
关键词
D O I
10.1158/1078-0432.CCR-06-2221
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Nuclear factor-kappa B (NF-kappa B) is a signal transcription factor that has emerged as an important modulator of altered gene programs and malignant phenotype in development of cancer. Major carcinogens and oncogenic viruses induce NF-kappa B activation, and a variety of subsequent oncogenic events contribute to a progressive increase in constitutive NF-kappa B activation as an important common pathway in most forms of cancer. NF-kappa B target genes promote tumor cell proliferation, survival, migration, inflammation, and angiogenesis. Inhibition of NF-kappa B has been found to be an important mechanism of action of steroids, nonsteroidal anti-inflammatory drugs, and natural and synthetic compounds that show therapeutic and preventive activity. Newer agents targeting the proteasome, inhibitor-kappa B kinase, and other upstream kinases involved in NF-kappa B activation have shown anticancer activity in clinical or preclinical studies.
引用
收藏
页码:1076 / 1082
页数:7
相关论文
共 100 条
  • [31] Guttridge DC, 1999, MOL CELL BIOL, V19, P5785
  • [32] Signaling to NF-κB
    Hayden, MS
    Ghosh, S
    [J]. GENES & DEVELOPMENT, 2004, 18 (18) : 2195 - 2224
  • [33] NF-κB as a therapeutic target in multiple myeloma
    Hideshima, T
    Chauhan, D
    Richardson, P
    Mitsiades, C
    Mitsiades, N
    Hayashi, T
    Munshi, N
    Dang, L
    Castro, A
    Palombella, V
    Adams, J
    Anderson, KC
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (19) : 16639 - 16647
  • [34] Nuclear factor κB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity
    Hinz, M
    Lemke, P
    Anagnostopoulos, I
    Hacker, C
    Krappmann, D
    Mathas, S
    Dörken, B
    Zenke, M
    Stein, H
    Scheidereit, C
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (05) : 605 - 617
  • [35] Hostile takeovers:: viral appropriation of the NF-κB pathway
    Hiscott, J
    Kwon, H
    Génin, P
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (02) : 143 - 151
  • [36] MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-κB-dependent proliferative advantage and resistance against FAS-induced cell death in B cells
    Ho, L
    Davis, RE
    Conne, B
    Chappuis, R
    Berczy, M
    Mhawech, P
    Staudt, LM
    Schwaller, J
    [J]. BLOOD, 2005, 105 (07) : 2891 - 2899
  • [37] Do older adults using NSAIDs have a reduced risk of colorectal cancer?
    Hoffmeister, Michael
    Chang-Claude, Jenny
    Brenner, Hermann
    [J]. DRUGS & AGING, 2006, 23 (06) : 513 - 523
  • [38] Sequential modification of NEMO/IKKγ by SUMO-1 and ubiquitin mediates NF-κB activation by genotoxic stress
    Huang, TT
    Wuerzbrger-Davis, SM
    Wu, ZH
    Miyamoto, S
    [J]. CELL, 2003, 115 (05) : 565 - 576
  • [39] The IKKNF-κB system:: A treasure trove for drug development
    Karin, M
    Yamamoto, Y
    Wang, QM
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (01) : 17 - 26
  • [40] Phosphorylation meets ubiquitination:: The control of NF-κB activity
    Karin, M
    Ben-Neriah, Y
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 : 621 - +